Leah Kuntz

The FDA has granted Fast Track designation to liafensine for the treatment of patients with treatment-resistant depression.

Do you want to be featured in our online series and potentially in print for an upcoming Special Report? Check out our October theme!

Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia.

New data informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of RBP-7000 (Perseris) to risperidone (Uzedy), an extended-release injectable suspension of risperidone for subcutaneous use every 1 or 2 months for the treatment of schizophrenia in adults.

Check out new positive efficacy, safety, and tolerability results from the phase 3 SOLARIS trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia.

A new analysis from a 3-year open-label extension study revealed that treatment with deutetrabenazine was associated with long term improvement of symptoms of tardive dyskinesia.

Enter your email to check out this complicated case!

A new study of adult emergency department admissions found that individuals taking high doses of amphetamine—like Adderall—have a 5-fold increased risk for developing psychosis or mania.

Learn more about the latest research related to 9/11 trauma and other psychiatric comorbidities.

DaylightRx becomes the very first FDA-cleared digital treatment for generalized anxiety disorder.

Abbott has initiated the TRANSCEND study to evaluate the use of deep brain stimulation to manage treatment-resistant depression.

Write to us now to be part of our series on forensic psychiatry!

Tomorrow, August 31, is Overdose Awareness Day. What can you be doing to help prevent overdose deaths?

What is new in research on major depressive disorder?

The first investigational, oral, muscarinic M4 selective agonist in development for the treatment of schizophrenia sees positive phase 2 results in the lowest tested dose.

New phase 1b results of VLS-01, an oral transmucosal film formulation of DMT, show ‘psychologically meaningful’ improvement for patients with treatment-resistant depression.

At least 1 in 2 people experience trauma at some point in their life, and a subset of those individuals will develop PTSD.

Write to us now to be part of our series on treatment updates this month.

The US Food and Drug Administration has approved Erzofri, a paliperidone palmitate extended-release injectable suspension for the treatment of adults with schizophrenia and schizoaffective disorder.

A supplemental New Drug Application has been submitted to the FDA seeking approval of esketamine (Spravato) CIII nasal spray as a monotherapy for adults with treatment-resistant depression.

The FDA has issued a complete response letter to Orexo for OX124, a high-dose naloxone nasal spray for opioid overdose reversal.

What is new in research on alcohol use disorder?

How are eating disorders different in LGBTQ+ patients compared with cisgender heterosexual patients? How can you best help manage eating disorders in this patient population?

New research found that among 8 first-line antidepressants, bupropion was associated with the least weight gain most consistently.

Psychiatric Times asked H. Steven Moffic, MD, to share his thoughts on humanitarianism and psychiatry.

Kisunla (donanemab-azbt) is now approved by the FDA for adults with early symptomatic Alzheimer disease.

Write to us now to be part of our series focused on schizophrenia this month.

While ketamine is a not approved for the treatment of depression or chronic pain, clinicians have shown increased interest in using it for these conditions. An FDA workshop is exploring its potential.

The FDA has approved its supplemental New Drug Application for Wakix tablets for the treatment of excessive daytime sleepiness in pediatric patients aged 6 years and older with narcolepsy.

The FDA has authorized the marketing of 4 menthol-flavored e-cigarette products in the United States through the premarket tobacco product application pathway.